Monalizumab

MCE 國際站：Monalizumab

CAS：1228763-95-8

品牌：MedChemExpress (MCE)

存儲條件：Please store the product under the recommended conditions in the Certificate of Analysis.

生物活性：Monalizumab (IPH2201) 是一種靶向自然殺傷細胞群 2A (NKG2A) 的免疫檢查點抑制劑。Monalizumab 是一種人源化抗 NKG2A 的單克隆抗體，可增加 IFN-γ 產(chǎn)生，從而促進自然殺傷細胞功能。Monalizumab 可用于頭頸部鱗狀細胞癌 (HNSCC) 的研究。

體外：Monalizumab 阻斷 NKG2A 并增強 CLL NK 細胞介導(dǎo)的針對表達 HLA-E 的 K562 細胞的細胞毒性[3]。Monalizumab 增強 Enzalutamide (HY-70002) (10 μM) 誘導(dǎo)的 NK 細胞活化和殺傷前列腺癌細胞 (LNCaP 和 22Rv1)[5]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only.

體內(nèi)：Monalizumab (50 μg，瘤內(nèi)注射，與 800 萬個活化的 NK 細胞一起) 可有效抑制免疫缺陷小鼠異種移植 HLA-E+ 腫瘤的腫瘤生長[4]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: immunodeficient mice xenografted with Cal-27 HLA-E high tumor cell[4] Dosage: 50?μg, together with 8?millions of activated NK cells Administration: intratumoral injections Result: Shows a synergestic antitumor effect. Enhanced NK-cell killing, and induces lysis of tumor cells. Clinical Trial

熱賣產(chǎn)品：Zinc sulfate (heptahydrate)  | Cimetidine  | SJ6986  | Tonabersat  | 5(6)-CFDA  | Shionone  | Saxagliptin  | TAT-GluA2 3Y  | Tomatidine  | Alfacalcidol

研究領(lǐng)域：Cell Cycle/DNA Damage  |  Immunology/Inflammation

作用靶點：Checkpoint Kinase (Chk)  |  IFNAR

熱門產(chǎn)品線：重組蛋白  |  化合物庫  |  天然產(chǎn)物  |  熒光染料  |  PROTAC  |  同位素標(biāo)記物  |  寡核苷酸

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides

參考文獻：

[1]. Thorbald van Hall, et al. Monalizumab: inhibiting the novel immune checkpoint NKG2A. J Immunother Cancer. 2019 Oct 17;7(1):263.[2]. Christian Borel, et al. Immunotherapy Breakthroughs in the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. Cancers (Basel). 2020 Sep 21;12(9):2691.[3]. McWilliams EM, et al. Therapeutic CD94/NKG2A blockade improves natural killer cell dysfunction in chronic lymphocytic leukemia. Oncoimmunology. 2016 Sep 9;5(10):e1226720.[4]. Melero I, et al. Intratumoral co-injection of NK cells and NKG2A-neutralizing monoclonal antibodies. EMBO Mol Med. 2023 Nov 8;15(11):e17804.[5]. Maximilian Pinho-Schwermann, et al. Androgen receptor signaling blockade enhances NK cell-mediated killing of prostate cancer cells and sensitivity to NK cell checkpoint blockade.doi doi.org/10.1101/2023.11.15.567201